INTRODUCTION
IFNs were the first cytokines discovered more than half a century ago as agents that interfere with viral infection (Borden et al., 2007; Isaacs and Lindenmann, 1957) . IFNs have been established as pleiotropic, multifunctional proteins in the early immune response, exhibiting antiproliferative effects on cells, in addition to their strong immunomodulatory and antiviral activities. Due to their potency and diverse biological activities, IFNs are used for the treatment of several human diseases, including hepatitis C, multiple sclerosis, and certain types of cancer (Borden et al., 2007) . Based on the receptor system that mediates their effects, IFNs are grouped into type I, type II, and type III IFNs . The type I IFNs act on, and are produced by, almost every nucleated cell and comprise 16 members with approximately 20%-60% sequence identity: IFNb, IFN 3, IFNk, IFNu, and 12 subtypes of IFNa. IFNa, IFNb, and IFNu are produced by cells exposed to viruses or double-stranded RNA (García-Sastre and Biron, 2006) and have been shown to possess antitumor activity (Horton et al., 1999; Pestka et al., 2004) as well as protect cells against parasites and bacterial pathogens (Bogdan, 2000) . Although similar in their spectrum of activities, IFNb, IFNu, and IFNa subtypes can vary significantly in their potency against different viruses, their antiproliferative activity, and their ability to activate cells of the immune system. The mechanism mediating this differential activity and signaling through a common receptor remains controversial (van Boxel-Dezaire et al., 2006) .
Despite their differential activities and broad range of potencies, all 16 human type I IFNs initiate signaling by binding to the same receptor composed of two subunits called IFNAR1 and IFNAR2. Together with the IL-10 family receptors, the IL-20 receptor, IL-22R, IL-22BP, IFNLR1, tissue factor, and IFNGR, IFNAR1 and IFNAR2 form the class II helical cytokine receptor family (Pestka et al., 2004; Walter, 2004; Zdanov, 2010) . In common with other class II helical cytokine receptors, the extracellular domain (ECD) of IFNAR2, whose nuclear magnetic resonance (NMR) structure has been characterized (Chill et al., 2003) , consists of two fibronectin III (FNIII)-like domains (D1 and D2). The ECD of IFNAR1, however, is unique, comprising a tandem array of four FNIII subdomains, designated SD1 to SD4, which arose from gene duplication of the typical two-domain structure (Gaboriaud et al., 1990 ).
The intracellular domains (ICDs) of IFNAR1 and IFNAR2 are associated with the Janus kinases (Jaks) Tyk2 and Jak1, respectively (Schindler and Plumlee, 2008; van Boxel-Dezaire et al., 2006) . Upon ligand binding by the IFNAR chains and formation of the extracellular signaling complex, these tyrosine kinases initiate a phosphorylation cascade principally mediated by STAT (signal transducer and activator of transcription) activation (Schindler and Plumlee, 2008) . Other important signaling pathways activated by type I IFNs include the phosphatidylinositol 3-kinase pathway and the MAP kinase pathway. Studies of the overlapping, yet differential cellular responses elicited by different members of the type I IFNs have suggested that the dynamics of ligand interaction with the receptor subunits plays a key role for regulating cellular response patterns (Jaitin et al., 2006; Jaks et al., 2007; Kalie et al., 2007) .
There are currently no crystal structures of type I IFN receptor complexes nor any complete receptor signaling complex in the class II helical cytokine family where structures of binary complexes of ligands (IFNg, IFNl) with their high-affinity receptor subunits are known (Bleicher et al., 2008 ; Jones et al., 2008; Josephson et al., 2001; Miknis et al., 2010; Walter et al., 1995) . Here we present structural and functional data that shed light on how type I IFNs engage their receptor chains, how the receptor system is able to recognize the large number of different ligands, and how the different chemistries of ligand interaction ultimately dictate the stabilities of the receptor complexes and therefore exert primary control on differential signaling.
RESULTS

Type I IFNs Exhibit Distinct Signaling and Functional Activities
We studied IFNs that differed significantly in their biological activities: IFNu, IFNa2, and a mutant of IFNa2, IFNa2(YNS), that was engineered to have higher affinity for IFNAR1 in order to improve its antitumor efficacy (Kalie et al., 2007) . We tested their relative antiviral and antiproliferative potencies, as well as another type I IFN, IFNa7 (Figures 1A and 1B and Figure S5 available online). The half-maximal effective concentration (EC 50 ) values in a hepatitis C replication assay showed 2-to 6-fold differences between the IFNs (IFNa7: 36 fM, IFNu: 37 fM, IFNa2(YNS): 20 fM, wild-type (WT) IFNa2: 116 fM) (Figure 1A) , whereas the antiproliferative activities on WISH cells differed by more than 1000-fold (EC 50 values: IFNa7: 1700 pM, IFNu: 490 pM, IFNa2(YNS): 1.5 pM, IFNa2(WT): 890 pM) ( Figure 1B ).
We used phospho-flow cytometry coupled with fluorescent cell barcoding to compare the intracellular signaling activities of these IFNs by measuring phosphorylation of STATs in primary cells in whole blood from human donors (Krutzik and Nolan, 2006) . This approach enabled us to measure IFN responses on endogenous IFN receptors of multiple cell subsets (B cells, monocytes, and CD8 and CD4 T cells) simultaneously without cell separation ( Figures 1C-1F , Figure S1 , and Figure S7 ). Although the potency of the different IFNs in inducing phosphorylation of STAT1 and STAT5 in monocytes is similar ( Figures 1C  and 1D ), IFNa2(YNS) has a lower EC 50 for p-STAT1 induction versus p-STAT3 and p-STAT5 ( Figure 1E ). Comparing the ratios of EC 50 (p-STAT1) versus EC 50 (p-STAT5) reveals that the different IFNs exhibit significant variability in different cell subsets ( Figure 1F ), with IFNa2(YNS) displaying the highest ratio of p-STAT1:p-STAT5 EC 50 values in B cells, CD4 T cells, and monocytes, and IFNu producing the lowest ratio in all three cell subsets. Collectively, the cellular and signaling results highlight the puzzling properties of differential signaling through the common IFNAR1-IFNAR2 heterodimeric receptor.
The Architecture of the IFN Ternary Signaling Complex
We determined crystal structures of a range of individual IFN receptor components, a subcomplex, and ternary complexes at various resolutions (Figure 2 and Table S1 ): (1) the structure of unliganded IFNAR1 comprising SD1 through SD3 (IFNAR1DSD4) at 1.9 Å ( Figure 2A) ; (2) the IFNAR2-D2 domain at 2.6 Å ( Figure 2B ); (3) the binary complex between IFNAR2 and IFNa2(HEQ) at 2.0 Å ( Figure 2C ); (4) the ternary ligandreceptor complex of IFNa2(YNS) (hereafter also referred to as IFNa2) at 4.0 Å ( Figure 2D ); (5) the ternary ligand-receptor complex of wild-type IFNu at 3.5 Å ( Figure 2E ). IFNa2(YNS) is a triple mutant (His57Tyr, Glu58Asn, Gln61Ser) of IFNa2 with high affinity for IFNAR1, and HEQ is the triple mutant to alanine (Jaitin et al., 2006) . High-resolution structures of subcomponents determined here, and previously (IFNa2 and IFNAR2-D1 domain) (Quadt-Akabayov et al., 2006; Radhakrishnan et al., 1996) , were used to solve the ternary complexes. Despite their lower resolution, the electron density maps of the ternary complexes (Figure S2 ) allowed refinement of almost all amino acids and clear visualization of conformational changes between the free and bound states (details in Extended Experimental Procedures). The SD4 of IFNAR1 has been shown to be unnecessary for IFN binding (Lamken et al., 2005) and, consistent with electronmicroscopic studies , it was not visible in the electron density maps. All structures can be viewed interactively at (http://proteopedia.org/w/Journal:Cell:1).
IFNAR1 and IFNAR2 bind on opposing sides of the IFN ligands in a nearly orthogonal architecture that has not been seen previously in crystal structures of cytokine-receptor complexes ( Figures 2D and 2E ). Both the IFNa2 and IFNu complexes exhibit almost identical overall receptor-ligand docking modes when the two ternary complexes are superimposed (root-mean-square deviation [rmsd] of Ca = 0.9 Å ) ( Figure 3A) . The IFNAR1-IFN docking mode seen here is unusual and so far without precedent among cytokine-receptor interactions. The IFNAR1-IFN interface is formed by residues of the SD1, SD2, and SD3 subdomains of IFNAR1 and by helices B, C, and D of the IFN molecule ( Figures 2D and 2E) , burying a total surface area of 2197 Å 2 (IFNu ternary complex). The IFN ligand primarily binds to IFNAR1 at the level of the hinge between the SD2 and SD3 domains, with the SD1 domain ''capping'' the top of the IFN molecule. In prior cytokine-receptor complexes of both the type I (e.g., human growth hormone, interleukin-2, erythropoietin, etc.) and type II (e.g., IFNg, IL-10, etc.) systems, the principal interaction mode is between the cytokine and the loops projecting from the ''elbow'' formed between two bent Fibronectin-III (FNIII) domains ( Figure 3B ) (Walter, 2004; Wang et al., 2009 ). In the case of IFNAR1, the SD2-SD3 tandem FNIII domains appear to be oriented in the opposite direction, such that the loops at the extreme top and bottom ends of the FNIII domains form the major contacts with the IFN ligands in a manner reminiscent of pinchers, whereas the elbow loops that normally bind to cytokines face outward into solvent. The SD1-SD2 tandem FNIII module engages the ligands in a manner that is more representative of a canonical cytokine-binding mode where the elbow contacts the ligand. As the SD1-SD2 and SD3-SD4 modules of IFNAR1 most likely arose by gene duplication, the relative orientation of the domains within the modules is thought to be similar, allowing us to model a position for SD4 ( Figure S3A ). However, its flexibility implies that there is interdomain variability in its position on a cell surface. Table S1 and Figure S2 .
On the opposing side of the ligand, both IFNAR2-IFN interfaces are formed between parts of helices A, E, and the A-B loop of the ligand and the IFNAR2-D1 domain and the loop between strands 13/14 in the D2 domain, burying $1841 Å 2 (IFNa2 binary complex) of surface area ( Figures 2D and 2E and Figure 4 ). On IFNAR2, the IFN ligand does not bind at the apex of the elbow region between the D1 and D2 domains of IFNAR2 as seen in most type I and II cytokine-receptor complexes (Figure 3B) , but rather almost all of the contact is with the receptor D1 domain. In the ternary complexes, the long axis of the IFN helical bundle is oriented perpendicularly to IFNAR1 but almost parallel to the beta sheets of the IFNAR2 D1 domain. The overall docking position of the ligands bound to IFNAR2 has global similarities to the manner in which the IFNg dimer engages IFNGR1 (Walter et al., 1995) and also to the IFNl-IFNLR1 complex (Figure 3B) (Miknis et al., 2010) . However, there are large differences in the relative receptor-IFN binding orientations between the different IFN types that clearly distinguish their recognition modes ( Figure S3B ). The rigid body ligand-binding topology to IFNAR2 is approximately similar to a docking model derived using constraints from NMR and mutagenesis (Nudelman et al., 2010) .
Mechanism of IFN Cross-reactivity versus Discrimination by IFNAR2
We compared the ligand-IFNAR2 interfaces from the binary IFNa2-IFNAR2 complex (2.0 Å resolution) ( Figures 4A-4D and Figure S2 ) and the IFNu ternary complex (3.5 Å resolution) See also Figure S2 and Table S2 .
( Figure 4E and Figure S2 ). We elucidated interactions that are conserved across type I IFNs (i.e., ''anchor points'') versus those that would be ligand specific ( Figure 4 and Figure 6 ). We also assembled previous alanine scanning data (Kalie et al., 2007; Piehler et al., 2000; Roisman et al., 2001 Roisman et al., , 2005 , together with new site-directed mutations prompted by the structures, in order to reconcile the structures with comprehensive energetic maps of the interfaces (Table S2) . Overall, most of the residues involved in the IFNa2-IFNAR2 interaction are also found in the IFNu-IFNAR2 interface of the IFNu ternary complex (Figures 4D and 4E) , highlighting that the basis of IFN cross-reactivity is through conservation of interactions rather than through highly divergent binding solutions. For clarity, in the two-dimensional contact maps of Figure 4 and Figure 5 , ligand-specific receptor contacts are circled in red, whereas those with divergent mutational consequences are circled in orange (Table S2 ). (Note: due to nonidentical sequence lengths [ Figure 6G ], the numbering of analogous IFNa2 and IFNu residues will often differ by one to three residues throughout the paper.) For example, Arg33 (Table  S2) . Thus, these are energetically critical, shared anchor points mediating IFN cross-reactivity. In contrast, the mechanism of ligand discrimination appears to derive in large part from differential energetics of shared contact positions among the different IFNs. A major ligand-specific difference between the IFNa and IFNu interfaces is related to Arg149 a2 in IFNa2, and the analogous Lys152 IFN in IFNu, and their respective interaction chemistries with Glu77 R2 . In the IFNa2-IFNAR2 interface, these two residues (R149A a2 and Glu77 R2 ) stabilize the interaction by forming a salt bridge ( Figures 4C and 4D ) that is worth about 1.9 kcal/mol in free energy ( Figure S4 ). Substituting Arg149 a2 by alanine reduces the affinity between IFNa2 and IFNAR2 by two orders of magnitude (Table S2 ). Arginine at position 149 is the consensus in all type I IFNs except IFNu, where it is replaced by Lys152 u , that forms an intramolecular salt bridge with Glu149 u and is within close proximity but is not directly contacting Glu77 R2 of the receptor. The differential contribution of Glu77 R2 to the two interfaces is reflected in the observation that its mutation to alanine differentially affects IFNa and IFNu binding: The IFNAR2(E77A) mutant binds IFNa2 with 60-fold lower affinity, whereas the affinity toward IFNu is reduced only 10-fold (Table  S2 , highlighted in orange). To mimic the connectivity of the IFNa2-binding interface, we made the Lys152Arg u swapping mutation (in addition to K152A), which increases omega binding by 5-fold (Table S2) 
IFNAR1 Forms a Diffuse and Broad Interface with the IFN Ligand
The IFNu and IFNa2(YNS) complexes are essentially identical in their binding footprints to IFNAR1 ( Figure 3A and Figure 5 ). We focus on the higher-resolution IFNu ternary complex for a detailed description of the IFN-IFNAR1 interfaces ( Figure S2 ). When the unliganded IFNAR1DSD4 structure and IFNAR1 of the ternary complexes are superimposed, it is apparent that the N-terminal SD1 domain and the SD2-SD3 portion of IFNAR1 move relative to each other upon IFN binding ( Figure 5A and Figures S3C and S3D) , allowing all three subdomains of IFNAR1 to contact the ligand. With the SD2-SD3 domains overlaid and fixed, the conformational change upon complex formation is a quasi-rigid body movement of the SD1 domain by about 10 Å down toward the ligand, bringing Asn68 R1 , Tyr70 R1 , and Figures 5D and 5F ). The interactions between 
Leu134
R1 , Phe238 R1 , and the phenylalanine in the ligand (Phe64 a2 in IFNa) are conserved in the IFNa-IFNAR1 interface ( Figure 5E ). Moreover, the contact between His236 R1 and an aspartate in the ligand is common to the interfaces of both IFNs ( Figures 5D and 5E ). It has been demonstrated that the three N-terminal FNIII domains of IFNAR1 (SD1-SD3) are necessary and sufficient for ligand binding (Lamken et al., 2005) . In particular, the SD1 segment spanning residues 62-70 is crucial for ligand binding and biological activity, with Val69 R1 and Tyr70 R1 as key residues (Cajean-Feroldi et al., 2004) . Their role is revealed by our ternary complex structures: Tyr70 R1 directly contacts the ligand ( Figures   5C and 5F ), whereas the preceding Val69 R1 stabilizes the S3-S4
loop. Tyr70 R1 and F238 R1 are the only hotspot residues in the ligand-binding site of IFNAR1 (Table S2) , highlighting its comparatively energetically flat binding surface compared to IFNAR2. Substituting these residues by alanine reduces the affinity to all tested IFN ligands by more than 10-fold (Table S2) .
Most interactions of the IFNu-IFNAR1 interface are conserved in the IFNa2-IFNAR1 interface (Figures 5D and 5E and Figures 6C and 6G (Table S2 , highlighted in orange).
IFNs Are Discriminated through Ligand-Specific Substitutions
In order to analyze the cross-reactivity of the type I IFN receptor, we mapped the interface contact residues and the residues conserved between IFNa2, IFNu, IFNb, IFN 3, and IFNk onto the surface of the IFN molecules in the ternary complexes (Figure 6) . A comparison of the maps of contact residues with the degree of sequence conservation reveals that IFNAR1 and IFNAR2 cross-react with different IFNs by using a few conserved residues on their ligands as anchor points against a background of less-or nonconserved amino acids ( Figures 6C, 6F , and 6G). As our mutational analysis has shown, ligand discrimination occurs primarily through distinct energetics of common contacts but also through small numbers of IFN subtype-or sequencespecific contacts. , Gln61 a2 , Phe64 a2 , and Arg120 a2 ; see Table S2 ).
Probing Differential IFN Signaling with Structure-Based Mutational Analysis
We analyzed two types of IFN mutations for their effects on signaling and function. We chose residues that differ in identity between IFNa2 and IFNu and either directly make energetically important receptor contacts in the structures or are in close proximity to residues that do. The first group includes Ala mutations of these residues (L26A
, as well as swaps of energetically important ''sister'' residues that are in corresponding positions (P28L u , K152R u ). A second group of mutations was designed to change the binding affinity to both receptors simultaneously. These were based on the IFNa2(YNS) variant (increases binding to IFNAR1 by $60-fold) and include YNS/M148A and YNS/L153A, which reduce binding to IFNAR2 by 30-and 10-fold, respectively (Table S2 ). Proteins harboring both mutations will have an altered balance between their affinities to IFNAR1 (higher affinity) and IFNAR2 (lower affinity). The mutant-binding affinities are shown in Table S2 . This extended set of mutations was then used to assess a range of functional consequences of IFN binding to the IFNAR1-IFNAR2 receptors:
(1) antiviral (AV) and antiproliferative (AP) activity (Figure 7 and Figure S5 ), (2) p-STAT activation with respect to EC 50 s and their relative ratios in different cell types from whole blood (Figures 8A and 8B and Figure S7 ), (3) gene expression (PKR, CXCL11, and TRAIL) in WISH cells ( Figure 8A and Figure S6 ), and (4) receptor internalization ( Figure 8C ). Antiviral and Antiproliferative Activity Structure-based mutations that result in loss of binding affinity also lead to a decrease in potency for both AV and AP activities and consequently reduce the functional distinction between IFNs ( Figure 7 and Figure S5 ). These data are in general accord with the stability model-antiviral activity is less affected by a loss in binding affinity than antiproliferative activity. Strikingly, mutations increasing binding affinity, as the ones observed for the mutants IFNa2(YNS) and IFNu(K152R), result in a significant increase of the AP activity, but not AV activity ( Figure 7B ). Indeed, the IFNu(K152R) gain-of-function mutant shows that a single substitution of the corresponding a2 residue results in IFNu behaving more like IFNa2(YNS). This supports the model that IFN-specific polymorphisms engaged in receptor contacts that energetically mediate complex stability play a major role in modulating IFN-specific functional activities ( Figure 7B ). These results also imply that intermediate affinities are sufficient to induce a maximal AV response, whereas much higher affinities are required to reach the maximal AP potency-in this respect the AP response is more ''tunable'' (Levin et al., 2011) .
p-STAT Activation
We used phospho-flow cytometry and fluorescent cell barcoding to measure phosphorylation levels of STAT1, 3, 4, and 5 in whole blood samples from two human donors (Figures 8A and 8B and Figure S7 ). Similar to the AV activity, the EC 50 values obtained for p-STAT activation proportionally increased for weaker binding mutants, whereas for the high-affinity mutants (IFNa2(YNS) and IFNu(K152R)) the same trend was not observed. Indeed, although IFNa2(YNS) induced slightly stronger STAT activation than IFNa2(WT), these differences were very small relative to their very substantial differences in affinity. Similarly, with the IFNu(K152R) mutant, despite its higher binding affinity, this mutant is somewhat less potent in p-STAT activation than IFNu(WT). These results are in accord with the current model that AV activity is well correlated with early p-STAT activation, and AV activity is nearly maximal even for weak binders. In contrast, the extent of STAT activation is not sufficient to explain the potency of the AP response. p-STAT Ratios Variable ratios of STAT activation in cell subsets is a striking example of differential signaling through a common receptor by different IFN subtypes ( Figure 1F ). We analyzed the p-STAT activation ratios induced by the high-affinity IFNa2(YNS) and IFNu(K152R) mutants, as well as the wild-type IFNs, IFNa2 and IFNu, in a mixed population of immune cells, i.e., whole blood samples from humans ( Figure 8B and Figure S7 ). Both mutants followed the same trend in deviations of p-STAT ratios relative to the wild-type IFNs, supporting the idea that by substituting a critical contact residue from one IFN into another, we have narrowed their functional distinction. As the principal effects of these substitutions are on affinity, this further suggests that the stability of the complex is the key determinant for functional distinction of IFNs and also highlights the utility of this metric as a readout of differential signaling activities by IFNs.
Receptor Internalization
We hypothesized that rapid receptor downregulation could be responsible for the nonproportional p-STAT activation observed for IFN mutants with increased binding affinity. Increased IFNAR2 downregulation by an IFNa2 mutant with increased binding affinity toward IFNAR1 has been observed (Jaitin et al., 2006; Marijanovic et al., 2007) . Here we show that mutants exhibiting higher binding affinity for IFNAR2 than WT induced a stronger IFNAR2 downregulation ( Figure 8C ) and faster decrease in p-STAT activation ( Figure 8D ). The IFNa2(YNS) reduced IFNAR2 by 60%, whereas the K152R u mutant almost completely eliminated surface IFNAR2, as opposed to wildtype IFNa2 or IFNu that only reduced the surface IFNAR2 by $50% ( Figure 8C ). Thus, increased binding affinities increase the propensity for receptor endocytosis, which leads to faster termination of signaling. The substantially stronger IFNAR2 downregulation exhibited by K152R u may explain the surprising increase in EC 50 of p-STATs seen for this mutant ( Figure 8A ) due to more rapid ( Figure 8C ) receptor inactivation in the endosome.
Gene Expression
We asked how receptor-binding affinity regulates the IFNinduced gene expression program. By rtPCR, we measured the levels of PKR, CXCL11, and TRAIL induction following 8 hr of treatment with the different IFN mutants ( Figure 8A and Figure S6-note that P28A u and M148A u were not included in the gene expression analysis). We found a uniform correlation between receptor-binding affinity and gene expression levels.
That is, mutants with reduced affinity had a higher EC 50 for induction of PKR, CXCL11, and TRAIL genes, whereas mutants with higher affinity had a lower EC 50 for induction of these genes. These data also indicate that the extent of STAT activation as measured by tyrosine phosphorylation does not fully explain the level of gene expression and AP response induced by the different IFN mutants, as in the case of the YNS and K152R u mutants. Although YNS is only marginally more potent in activating STATs than IFNa2(WT), it is significantly more potent in inducing TRAIL, PKR, and CXCL11 than IFNa2(WT). Interestingly, whereas the EC 50 for PKR gene expression activation is $50-fold lower for most IFNs than the one measured for TRAIL or CXCL11, these ratios are significantly smaller ($15-fold) for the three YNS a2 variants and for the K152R u mutant (Figure S6 ), suggesting that tighter-binding IFNs lose some of this differential gene activation, perhaps by sacrificing tunability for affinity.
DISCUSSION
Type I interferons were discovered over 50 years ago as antiviral agents. Subsequent research has shown that the many IFN subtypes show differential activities through common receptor chains. Our studies show that the overall architectures of receptor binding to both IFNa2 and IFNu are nearly identical ( Figure 3A) , and that the answer to how different IFNs are capable of inducing differential functional effects appears to be ligand discrimination through distinct receptor-binding chemistries, which dictate the respective stabilities of the receptor-ligand interactions. The distinct binding chemistries are achieved primarily by differential energetics of shared anchor points and, to a lesser extent, by key amino acid substitutions between IFNs. These ligand-specific differences in the extracellular complex stabilities manifest as perturbations in downstream signaling cascades, in both linear and nonlinear fashions. Mechanistically, different complex stability kinetics could control the relative Jak/Tyk activity toward intracellular substrates of greater or lesser accessibility, which would in turn lead to distinct downstream effector activation profiles and ultimately impact induction of IFN-responsive genes. In this respect, recognitionmediated tuning of differential signaling by the type I IFN receptor system is quite unique for a transmembrane receptor but has parallels to the antigen ''proofreading'' ability of the T cell receptor to differentially respond to self and foreign peptide-MHC molecules presenting subtly different peptide recognition chemistries. In the context of prior cytokine receptor structures, IFNAR1 is particularly striking, with participation of three subdomains and a conformational change upon IFN binding (Figure 5A and Figure S3) . That this is a bona fide ligand-induced conformational change is corroborated by the importance of the SD1 domain for ligand binding and by FRET measurements suggesting conformational changes in the ectodomain of IFNAR1 upon IFN binding . The conformational change in IFNAR1 is required to form the full spectrum of interactions with the ligand and to allow the formation of a ternary complex that is stable enough to facilitate transphosphorylation between Jak1 and Tyk2. Thus, ligand binding to IFNAR1 will be accompanied by an energetic cost associated with the structural rearrangements required to bring a key hotspot residue into contact and could play a role in tuning responsiveness to different IFN ligands. We suggest that the required conformational change contributes to the reduced binding affinity of IFNAR1 and may result in tighter control of IFN signaling.
In addition to the conformational change, the role of IFNAR1 in ligand responsiveness is also unique compared to IFNAR2. IFNAR1 is not optimized for high binding affinity but rather for functional plasticity. That is, in contrast to the interaction with IFNAR2, binding energy is distributed over a large number of amino acid contacts with relatively low individual contributions and with much lower cooperativity, altogether resulting in lower affinity. For early STAT activation, which is required for the antiviral cellular response, transient ligand interaction with IFNAR1 appears to be advantageous (Moraga et al., 2009) . High stability of the ternary complex seems to be more important for a subset of IFN activities requiring prolonged activation of IFN signaling pathways (Coelho et al., 2005; Jaitin et al., 2006) . The relatively large binding interface of IFNAR1 for IFN involving three FNIII-like domains provides a versatile means for fine-tuning the binding affinity toward different IFNs and tailoring differential response patterns.
The molecular basis of IFNAR cross-reactivity is unique compared with other shared receptor systems, such as gp130 and common gamma chain (g c ), and this likely reflects the fact that the IFN interaction chemistry controls signal initiation. gp130 engages different cytokines through entirely distinct binding surfaces that do not appear to share anchor points, whereas g c engages in degenerate binding largely through shape complementarity (Wang et al., 2009) . What sets the IFNAR system apart is that the IFNAR1/2 heterodimer recognizes and transduces the signal for all 16 IFN subtypes, whereas in the other shared cytokine receptors, signal specificity is determined by different ligand-specific coreceptors heterodimerizing with the shared receptor. In this way, the recognition chemistries of gp130 and g c are not important arbiters of signaling specificity.
With regards to function, our mutational and substitution experiments suggest a model whereby ablating or swapping key IFN-specific residues that engage in receptor interactions narrows the functional distinction between IFNs. Importantly, however, the mutational analysis also shows that the local environment of these contacts plays an important role in determining their energetic values in the respective IFN complexes. Mutation of individual positions has complicated energetic consequence. Therefore, ligand-specific residues are not ''plugand-play'' in a manner that easily allows one to recapitulate IFN subtype behavior by point mutagenesis. This is to be expected given that the functional distinction of IFN ligands arose, in part, through coevolution of broad receptor-ligand interaction surfaces over hundreds of millions of years. A surprising exception to this was the K152R gain-of-function mutation in IFNu, which, clearly, is a highly modular contact point.
Ligand-specific differences in the stabilities of the complexes are also reflected in variances in the kinetics of receptor downregulation, which terminates signaling. Our studies revealed that increased binding affinities toward IFNAR1 (IFNa2(YNS) mutant) or IFNAR2 (IFNu(K152R) mutant) strongly enhance receptor downregulation, which very likely explains a much more rapid decline in p-STAT activation compared to IFNa2(WT) and IFNu(WT). Increased IFNAR2 downregulation by the higheraffinity IFNb, compared to IFNa2, has been previously suggested to be responsible for differential cellular responses (Jaitin et al., 2006; Kalie et al., 2007) . Here, we have designed an IFN mutant with increased binding affinity toward IFNAR2, which surprisingly induces even stronger downregulation of IFNAR2. Increased IFNAR2 downregulation could explain why the substantially increased binding affinity of these IFN mutants is not accompanied by a significant increase in their AV potency because it is very likely responsible for a rapid decrease in p-STAT levels, as seen after stimulation with IFNa2(YNS) and IFNu(K152R).
In contrast to AV activity, which requires only very low doses of IFN to reach saturation, AP activity benefits from an increased binding affinity (Kalie et al., 2008) . Cells need to sense very low levels of IFN and act very fast in order to clear viral infections in their initial stages. On the other hand, antiproliferative activity, which is often linked with apoptosis and tissue damage, needs to be under tighter control to prevent unnecessary damage. These activities will therefore be more tunable over a broad range to changes in the kinetics and strength of the downstream signaling. IFNs, by forming a gradient of complex stabilities, will induce specific profiles of signal activation that will lead to diverse antiproliferative potencies. Taken together, differential IFN signaling activities are mediated by both nonlinear signaling and nonlinear receptor desensitization mechanisms. This type of ''ligand proofreading'' provides a mechanistic model, now together with a structural framework, for how a common receptor can respond in a graded fashion to different ligands.
EXPERIMENTAL PROCEDURES Transient Hepatitis C Virus Replication Assay
The transient hepatitis C virus (HCV) replication assay was performed using Huh7.5 cells and a Luciferase reporter system as previously described (Cho et al., 2010) . Additional details for this and subsequent experimental procedures can be found in the Extended Experimental Procedures.
Antiproliferative Activity Assay Antiproliferative assays were performed using WISH cells as described in Moraga et al. (2009) .
Protein Expression, Purification, and Complex Formation
The following proteins used in this study were expressed as C-terminally his-tagged constructs from baculovirus using the pAcGp67A vector: human IFNu (including all IFNu mutants), IFNa7, IFNa2(HEQ), IFNAR1DSD4 (amino acids 3-305), full-length IFNAR1 ectodomain, IFNAR2 (amino acids 10-205), IFNAR2-D2 (amino acids 104-205). IFNAR2 used in the binary complex was secreted by Hi-5 cells in the presence of Tunicamycin at a concentration of 0.5 mg/l. IFNAR2 (amino acids 7-205) used for IFNu(N80Q) ternary complex formation was expressed using the BacMam expression vector pVL-AD6-L (Dukkipati et al., 2008) (Kalie et al., 2007) . Prior to crystallization, all proteins were treated with 3C protease/TEV protease and/or carboxypeptidases A and B to remove C-terminal his-tags. Selenomethionine (SeMet)-labeled proteins from baculovirus were prepared according to a protocol published earlier (Dong et al., 2009 ). The IFNu(N80Q) ternary complex was formed by mixing IFNAR1 and IFNu(N80Q) from insect cells with IFNAR2 expressed in HEK293 cells. The IFNa2(YNS) ternary complex was formed by mixing IFNAR1 and IFNAR2 from insect cells and IFNa2(YNS) expressed in E. coli. The complexes were formed by mixing individually purified components in approximately stoichiometric ratios; the complexes were purified by gel filtration.
Crystallization and X-Ray Data Collection
All crystallization experiments were carried out using hanging-drop vapor diffusion at 20 C. Individual crystallization conditions can be found in the Extended Experimental Procedures. Datasets on frozen crystals were collected at beamlines 9.1 (SeMet-IFNAR1DSD4), 9.2 (osmium-derivatized IFNAR1DSD4; SeMet-IFNAR2-D2), and 11.1 (native dataset of IFNAR1DSD4) of the Stanford Synchrotron Radiation Lightsource (SSRL) and at beamlines 8.2.1 (IFNa2(YNS) ternary complex) and 8.2.2 (IFNa2(HEQ)-IFNAR2 binary complex; IFNu(N80Q) ternary complex) of the Advanced Light Source (ALS), Berkeley. All data were indexed, integrated, and scaled with the XDS package (Kabsch, 1993) .
Structure Determination and Refinement
Phases for IFNAR1DSD4 were obtained by single isomorphous replacement with anomalous scattering (SIRAS) in the program autoSHARP (Vonrhein et al., 2007) using the osmium derivative and the native dataset.
The structure of the SeMet-labeled IFNAR2-D2 domain was determined by single-wavelength anomalous diffraction (SAD) using autoSHARP.
The IFNa2(HEQ)-IFNAR2 binary complex, IFNa2(YNS) ternary complex, and IFNu(N80Q) ternary complex were all solved by molecular replacement with the program Phaser (McCoy et al., 2007) . All X-ray structures described were refined with Phenix (Adams et al., 2010) . Molecular graphics images were prepared using PyMOL (Schrö dinger).
Affinity Measurements
All binding data of IFNs and the ECD of IFNAR2 were determined by surface plasmon resonance on a ProteOn XPR36 machine (BIO-RAD) using purified proteins. Binding of IFNa2(YNS) and IFNu to immobilized IFNAR1 was probed by simultaneous total internal reflection fluorescence spectroscopy (TIRFS) and reflectance interference (RIF) detection.
Phospho-Flow Analysis of Intracellular Signaling
Analysis of intracellular signaling in whole blood was performed as previously described (Krutzik and Nolan, 2006) . Briefly, whole blood samples from two donors were warmed to 37 C and stimulated with increasing concentrations of the appropriate cytokine for 30 min. After samples were fixed and lysed, samples were fluorescently barcoded with DyLight 800 and Pacific Orange dyes as previously described. After barcoding and combining, samples were stained for 1 hr with CD3 PE, CD4 Pacific Blue, CD20 PerCP-Cy5.5, CD33 PE-Cy7, and a combination of p-STAT1 Ax647 and p-STAT3 Ax488 or p-STAT5 Ax647 and p-STAT4 Ax488. Analysis was performed on a Becton Dickinson LSRII equipped with 405, 488, and 633 nm lasers. Data analysis was performed in Cytobank software. Log median fluorescence intensity values were plotted against cytokine concentration to yield dose-response curves.
Analysis of IFNAR2 Downregulation
Downregulation experiments were performed using Ramos cells stimulated with IFN proteins for 5 min, followed by anti-IFNAR2 monoclonal antibody (mAb) staining as described in Jaitin et al. (2006) and Marijanovic et al. (2007) .
Analysis of STAT Phosphorylation Kinetics
Ramos cells were stimulated with 10 nM of IFN mutants for the indicated times according to the protocol in Marijanovic et al. (2007) . Samples were analyzed by phospho-flow cytometry.
Quantitative PCR Selected human IFN-stimulated gene expression levels were measured with the ABI Prism 7300 Real-Time PCR System using previously described methods (Levin et al., 2011) . 
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